Middle East And Africa Breast Cancer Diagnostics Market
市场规模(十亿美元)
CAGR : %
Forecast Period |
2024 –2030 |
Market Size (Base Year) |
|
Market Size (Forecast Year) |
USD 405.56 |
CAGR |
|
Major Markets Players |
中东和非洲乳腺癌诊断市场,按测试类型(成像、活检、基因组测试、血液测试等)、类型(导管原位癌、浸润性导管癌、炎性乳腺癌和转移性乳腺癌)、最终用户(医院、诊所、研究和学术机构、诊断中心等)分销渠道(直接招标、零售销售等)行业趋势和预测到 2030 年。
中东和非洲乳腺癌诊断市场分析与洞察
乳腺癌是人群中最常见的疾病,主要发生在患有增生性疾病的女性身上。乳腺癌主要发生在乳腺组织中。乳腺癌的症状包括乳房肿块、乳房大小和形状的差异、乳头分泌物以及皮肤上发炎、鳞状红斑。随着药物的增长,乳腺癌市场的增长,女性乳腺癌的发病率每次都会增加。先进的乳腺癌诊断方法与发达的技术。通过提高乳腺癌的有效性、准确性、效率、可靠性和结果速度以及改善疾病检测来改进乳腺癌开发的技术。先进的功能可以在更短的时间内检测出癌症。癌症在早期被发现,这有助于患者更快地康复,防止癌细胞扩散到身体的其他部位,并使用市场上的新药物进行治疗。肿瘤筛查和成像的增加将推动乳腺癌市场的发展。这正在扩大乳腺癌市场,每年患者数量都在增加,乳腺癌的康复率也在提高。政府通过增加新药开发项目的可用性、提高治疗的有效性和效率以及将新药整合到医疗领域来提供支持。
然而,癌症诊断治疗成本高以及缺乏熟练的专业人员是制约市场增长的因素。
Data Bridge Market Research 分析称,中东和非洲乳腺癌诊断市场预计到 2030 年将达到 4.0556 亿美元的价值,预测期内的复合年增长率为 7.1%。由于乳腺癌患者人数不断增加以及中东和非洲乳腺癌治疗技术不断进步,检测类型占据了市场中最大的诊断类型部分。本市场报告还深入介绍了定价分析、专利分析和技术进步。
报告指标 |
细节 |
预测期 |
2023 至 2030 年 |
基准年 |
2022 |
历史岁月 |
2021 (可定制为 2020-2016) |
定量单位 |
收入(百万美元)、销量(单位)、定价(美元) |
涵盖的领域 |
按测试类型(成像、活检、基因组测试、血液测试等)、类型(导管原位癌、浸润性导管癌、炎性乳腺癌和转移性乳腺癌)、最终用户(医院、诊所、研究和学术机构、诊断中心等)分销渠道(直接招标、零售销售等)。 |
覆盖国家 |
南非、沙特阿拉伯、阿联酋、埃及、以色列以及中东和非洲其他地区。 |
涵盖的市场参与者 |
在市场上开展业务的主要公司包括 F-Hoffmann La Roche Ltd.、Siemens Healthcare GmbH、通用电气、Koninklijke Philips NV、富士胶片株式会社、雅培、Hologic, Inc.、OncoStem、Provista Diagnostics、赛默飞世尔科技公司、Myriad Genetics, Inc.、Illumina, Inc.、Bio-Rad Laboratories, Inc.、BD、NanoString.、Cepheid、BIOMÉRIEUX、Exact Sciences Corporation、Biocept, Inc. 和 Abacus ALS 等。 |
中东和非洲乳腺癌诊断市场定义
乳腺癌是一种乳腺组织中恶性细胞不受控制生长的疾病,女性比男性更常见。乳腺癌是乳腺细胞不受控制的细胞分裂,乳腺细胞是乳腺和乳腺管中最常见的细胞。乳腺癌的一些症状包括乳房肿块或肿块、乳头流血以及乳头或乳房形状的改变。乳腺癌的治疗取决于癌症的分期。其治疗包括化疗、放射疗法、激素疗法和手术。
乳腺癌是另一种女性比男性更常见的癌症。这种疾病的一些症状包括生殖器官分泌出血、乳房内出现肿块或阻塞,以及乳房或乳头的质地或形状发生变化。乳腺癌的治疗取决于癌症的分期。此外,其治疗包括放射治疗、疗法、激素治疗和手术。早期发现癌症对于有效治疗该疾病至关重要。早期发现该疾病还可以带来更好的结果,包括多种治疗选择、更好的生存率和更好的生活质量。由于疾病的迅速传播,对新治疗形式或治疗方法的压力和需求不断增加。
中东和非洲乳腺癌诊断市场动态
本节旨在了解市场驱动因素、优势、机遇、限制和挑战。下面将详细讨论所有这些内容:
驱动程序
- 推出技术先进的诊断和治疗技术以促进增长
乳腺癌是人群中最常见的疾病,主要发生在患有增生性疾病的女性身上。乳腺癌发生在乳腺组织中。乳腺癌的症状包括乳房肿块、乳房大小和形状的差异、乳头分泌物以及皮肤上出现瘙痒、鳞状红斑。这种疾病在体内蔓延,症状不断增加,如骨痛、淋巴结肿大、呼吸困难等。加大对乳腺癌新技术和治疗方法的研发力度将大大促进市场增长。
此外,成像技术的进步为筛查和早期检测的改进创造了新的机会。其中一项技术进步是 3D 乳房 X 线摄影,也称为乳房断层合成。该程序从乳房周围的不同角度拍摄图像,并将其构建成类似 3D 的图像。
近年来,多项技术进步正在改变癌症诊断的命运,正如上文提到的一些最新进展,其他几项技术目前正处于试验阶段,即将改变乳腺癌诊断的过程。该领域的这些技术进步是中东和非洲乳腺癌诊断市场的主要推动力。
- 乳腺癌发病率不断上升
推动中东和非洲市场增长的主要因素之一是全球乳腺癌的发病率不断上升,预计这将导致大量患者需要准确有效的治疗方案。乳腺癌是世界上最常见的癌症之一,更好的诊断技术有望在未来增加确诊患者的数量。
此外,预防保健和早期治疗的需求不断增长,导致了许多癌症筛查,这也将增加预测期内需要高治疗的患者数量。
因此,乳腺癌患病率的上升导致病例的诊断增多,因此预计在预测期内将推动市场增长。
克制
- 乳腺癌治疗的不良反应
筛查是在患者出现任何症状之前寻找癌症。这有助于在早期发现癌症。如果及早发现异常组织或癌症,治疗起来可能更容易。当出现症状时,癌症可能已经开始扩散。有几种筛查测试可用于检测乳腺癌,包括乳房磁共振成像、诊断性乳房 X 光检查、活检等。虽然这些测试被认为是诊断乳腺癌的标准方法,但它们也有相关风险,包括假阴性结果、假阳性结果,以及副作用,如过度的心理压力、过度的辐射暴露,以及肿瘤破裂和癌细胞扩散的严重风险。
机会
- 政府采取的举措
政府正致力于通过先进的技术增加乳腺癌治疗的主动性,以改善患者的健康状况。提供保险等福利的数量有所增加,以便普通人可以选择治疗并利用可用的药物和治疗方法来改善他们的生活质量。在中国和印度等发展中国家,政府已经启动了多项计划和举措,以提高人们对这种疾病的认识。这大大增加了对乳腺癌诊断和疾病管理疗法的需求。制药公司和政府机构之间不断增加的并购是中东和非洲乳腺癌市场的主要趋势之一。
2010 年至 2019 年,乳腺癌新发病例率每年上升 0.6%,死亡率同期平均每年上升 1.7%。随着乳腺癌患者率的上升,用于癌症诊断的治疗方法和先进技术的使用将会增加,这是市场增长的机会。
挑战
- 缺乏诊断基础设施
乳腺癌等非传染性疾病和其他类型的癌症现已被联合国和世卫组织认定为重大公共卫生危机。癌症是这一问题的最大组成部分,卫生系统面临着改善癌症护理、控制成本和提高系统效率的重大挑战。高收入国家与低收入和中等收入国家在治疗方法和结果方面的差异是惊人的。造成这种差异的原因包括成本、获得护理的机会、劳动力和培训差距以及外行和医疗界缺乏认识。
此外,与早期诊断相比,癌症筛查是一项独立且更为复杂的公共卫生战略,需要额外的资源、基础设施和协调。不同地区的农村、发展中国家和低收入国家没有足够的基础设施来维持新试剂盒和样品储存。这些国家需要诊断基础设施来确保疾病的早期发现和快速、准确的诊断。
新冠肺炎疫情对中东和非洲乳腺癌诊断市场的影响
新冠肺炎疫情导致与乳腺癌筛查、癌前护理和异常筛查结果管理相关的选择性医疗服务中断。这可能导致乳腺癌发病率上升,加剧现有的健康不平等。
制造商正在制定各种战略决策,以在新冠疫情后实现复苏。参与者正在进行多项研发活动、产品发布和战略合作,以改进市场所涉及的技术和测试结果。
最新动态
- 2022 年 11 月,荷兰皇家飞利浦公司在北美放射学会 (RSNA) 年会上宣布在中东和非洲推出下一代紧凑型便携式超声解决方案,旨在为更多患者带来与高级推车式超声系统相关的诊断质量。它便携且用途广泛,具有良好的图像质量或性能。它与飞利浦超声系统 Affiniti 和 EPIQ 换能器兼容。这有助于公司扩大其产品组合。
- 2022 年 11 月,西门子医疗与 Atrium Health 宣布建立多年期价值合作伙伴关系 1。Atrium Health 是一家领先的非营利性医疗保健提供商,以领先的儿科、癌症和心脏护理项目而闻名。这项战略协议的重点是改善 Atrium Health 在美国东南部服务区的医疗服务可及性,改善健康公平性并提高经济流动性。Atrium Health 正在从西门子医疗收购价值超过 1.4 亿美元的设备和器械,包括先进的成像技术、放射肿瘤学和精密血管内机器人。这有助于该公司扩大业务。
中东和非洲乳腺癌诊断市场范围
中东和非洲乳腺癌诊断市场细分为检测类型、类型、最终用户和分销渠道。细分市场之间的增长有助于您分析利基增长领域和进入市场的策略,并确定您的核心应用领域和目标市场的差异。
中东和非洲乳腺癌诊断市场(按检测类型)
- 成像
- 活检
- 基因测试
- 验血
- 其他的
根据测试类型,中东和非洲乳腺癌诊断市场分为成像、活检、基因组测试、血液测试和其他。
中东和非洲乳腺癌诊断市场(按类型)
- 导管原位癌
- 浸润性导管癌
- 炎性乳腺癌
- 转移性乳腺癌
根据类型,中东和非洲乳腺癌诊断市场分为导管原位癌、浸润性导管癌、炎性乳腺癌和转移性乳腺癌。
中东和非洲乳腺癌诊断市场(按最终用户划分)
- 医院
- 诊所
- 研究与学术机构
- 诊断中心
- 其他的
根据最终用户,中东和非洲乳腺癌诊断市场分为医院、诊所、研究和学术机构、诊断中心和其他。
中东和非洲乳腺癌诊断市场,按分销渠道划分
- 直接招标
- 零售销售
- 其他的
根据分销渠道,中东和非洲乳腺癌诊断市场分为直接招标、零售和其他。
中东和非洲乳腺癌诊断市场区域分析/见解
对中东和非洲乳腺癌诊断市场进行了分析,并提供了市场规模信息,包括测试类型、类型、最终用户和分销渠道。
本市场报告涵盖的国家包括南非、沙特阿拉伯、阿联酋、埃及、以色列以及中东和非洲其他地区。
2023 年,埃及将主导中东和非洲市场,因为对乳腺癌研发的投资增加预计将推动市场增长。
报告的国家部分还提供了影响单个市场因素和国内市场监管变化,这些因素和变化会影响市场的当前和未来趋势。新销售、替代销售、国家人口统计、监管法案和进出口关税等数据点是用于预测单个国家市场情景的一些主要指标。此外,在对国家数据进行预测分析时,还考虑了中东和非洲品牌的存在和可用性以及它们因来自本地和国内品牌的激烈或稀少竞争而面临的挑战,以及销售渠道的影响。
竞争格局和中东和非洲乳腺癌诊断市场份额分析
中东和非洲乳腺癌诊断市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、生产基地和设施、公司优势和劣势、产品发布、产品试验渠道、产品批准、专利、产品宽度和广度、应用优势、技术生命线曲线。以上提供的数据点仅与公司对中东和非洲乳腺癌诊断市场的关注有关。
中东和非洲乳腺癌诊断市场的一些主要参与者包括 F-Hoffmann La Roche Ltd.、西门子医疗有限公司、通用电气、荷兰皇家飞利浦公司、富士胶片株式会社、雅培、Hologic 公司、OncoStem、Provista Diagnostics、赛默飞世尔科技公司、Myriad Genetics 公司、Illumina 公司、Bio-Rad Laboratories 公司、BD、NanoString、Cepheid、BIOMÉRIEUX、Exact Sciences 公司、Biocept 公司和 Abacus ALS。
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
目录
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTIC MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 MARKET END USER COVERAGE GRID
2.8 TEST TYPE LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER'S 5 FORCES
5 EPIDEMIOLOGY
6 INDUSTRIAL INSIGHTS
7 REGULATORY FRAMEWORK
8 MARKET OVERVIEW
8.1 DRIVERS
8.1.1 LAUNCH OF TECHNOLOGICALLY ADVANCED DIAGNOSIS & THERAPEUTICS TO AID GROWTH
8.1.2 INCREASING PREVALENCE OF BREAST CANCER
8.1.3 GROWING IMPORTANCE OF WOMEN'S HEALTH
8.1.4 RISING AWARENESS TOWARDS THE BREAST CANCER
8.2 RESTRAINTS
8.2.1 ADVERSE EFFECTS OF BREAST CANCER THERAPEUTICS
8.2.2 HIGH COST OF THE IMAGING SYSTEMS
8.3 OPPORTUNITIES
8.3.1 INITIATIVES TAKEN BY THE GOVERNMENT
8.3.2 STRATEGIC INITIATIVES TAKEN BY THE KEY MARKET PLAYERS
8.3.3 GROWTH IN RESEARCH AND DEVELOPMENT OF BREAST CANCER
8.4 CHALLENGES
8.4.1 LACK OF DIAGNOSTIC INFRASTRUCTURE
8.4.2 LACK OF SKILLED PROFESSIONALS FOR PROPER DIAGNOSIS OF BREAST CANCER
9 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE
9.1 OVERVIEW
9.2 IMAGING
9.2.1 IONIZING BREAST IMAGING TECHNOLOGIES
9.2.1.1 FULL-FIELD DIGITAL MAMMOGRAPHY (FFDM)
9.2.1.2 ANALOG MAMMOGRAPHY
9.2.1.3 3D BREAST TOMOSYNTHESIS
9.2.1.4 POSITRON EMISSION TOMOGRAPHY/ COMPUTED TOMOGRAPHY (PET/CT)
9.2.1.5 MOLECULAR BREAST IMAGING/ BREAST SPECIFIC GAMMA IMAGING (MBI/BSMI)
9.2.1.6 POSITRON EMISSION MAMMOGRAPHY
9.2.1.7 OTHERS
9.2.2 NON-IONIZING IMAGING TECHNOLOGIES
9.2.2.1 OPTICAL IMAGING
9.2.2.2 BREAST ULTRASOUND
9.2.2.3 BREAST MRI (MAGNETIC RESONANCE IMAGING)
9.2.2.4 AUTOMATED WHOLE BREAST ULTRASOUND (AWBU)
9.2.2.5 BREAST THERMOGRAPHY
9.2.3 BIOPSY
9.2.3.1 SURGICAL BIOPSY
9.2.3.2 FINE NEEDLE ASPIRATION BIOPSY
9.2.3.3 CORE NEEDLE BIOPSY
9.2.3.4 IMAGE-GUIDED BIOPSY
9.2.3.5 SENTINEL LYMPH NODE BIOPSY
9.2.4 GENOMIC TEST
9.2.4.1 MOLECULAR TESTING
9.2.4.1.1 PD-L1
9.2.4.1.2 MICROSATELLITE INSTABILITY-HIGH (MSI-H) OR DNA MISMATCH REPAIR DEFICIENCY (DMMR)
9.2.4.1.3 NTRK GENE FUSIONS
9.2.4.1.4 PI3KCA GENE MUTATION
9.2.4.2 MAMMAPRINT
9.2.4.3 ONCOTYPE DX
9.2.4.4 OTHERS
9.3 BLOOD TEST
9.4 OTHERS
10 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET, BY TYPE
10.1 OVERVIEW
10.2 INVASIVE DUCTAL CARCINOMA
10.3 DUCTAL CARCINOMA IN SITU
10.4 INFLAMMATORY BREAST CANCER
10.5 METASTATIC BREAST CANCER
11 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET, BY END USER
11.1 OVERVIEW
11.2 HOSPITALS
11.3 DIAGNOSTICS CENTERS
11.4 CLINICS
11.5 RESEARCH & ACADEMIC INSTITUTES
11.6 OTHERS
12 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL
12.1 OVERVIEW
12.2 DIRECT TENDER
12.3 RETAIL SALES
12.4 OTHERS
13 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET, BY REGION
13.1 MIDDLE EAST AND AFRICA
13.1.1 EGYPT
13.1.2 SOUTH AFRICA
13.1.3 ISRAEL
13.1.4 SAUDI ARABIA
13.1.5 UAE
13.1.6 REST OF MIDDLE EAST AND AFRICA
14 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET, COMPANY LANDSCAPE
14.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA
15 SWOT ANALYSIS
16 COMPANY PROFILE
16.1 HOLOGIC, INC.
16.1.1 COMPANY SNAPSHOT
16.1.2 REVENUE ANALYSIS
16.1.3 COMPANY SHARE ANALYSIS
16.1.4 PRODUCT PORTFOLIO
16.1.5 RECENT DEVELOPMENTS
16.2 SIEMENS HEALTHCARE GMBH
16.2.1 COMPANY SNAPSHOT
16.2.2 REVENUE ANALYSIS
16.2.3 COMPANY SHARE ANALYSIS
16.2.4 PRODUCT PORTFOLIO
16.2.5 RECENT DEVELOPMENTS
16.3 F. HOFFMANN- LA ROCHE LTD
16.3.1 COMPANY SNAPSHOT
16.3.2 REVENUE ANALYSIS
16.3.3 COMPANY SHARE ANALYSIS
16.3.4 PRODUCT PORTFOLIO
16.3.5 RECENT DEVELOPMENTS
16.4 KONINKLIJKE PHILIPS N.V.
16.4.1 COMPANY SNAPSHOT
16.4.2 REVENUE ANALYSIS
16.4.3 COMPANY SHARE ANALYSIS
16.4.4 PRODUCT PORTFOLIO
16.4.5 RECENT DEVELOPMENTS
16.5 ABBOTT
16.5.1 COMPANY SNAPSHOT
16.5.2 REVENUE ANALYSIS
16.5.3 COMPANY SHARE ANALYSIS
16.5.4 PRODUCT PORTFOLIO
16.5.5 RECENT DEVELOPMENTS
16.6 ABACUS ALS
16.6.1 COMPANY SNAPSHOT
16.6.2 PRODUCT PORTFOLIO
16.6.3 RECENT DEVELOPMENTS
16.7 BD
16.7.1 COMPANY SNAPSHOT
16.7.2 REVENUE ANALYSIS
16.7.3 COMPANY SHARE ANALYSIS
16.7.4 PRODUCT PORTFOLIO
16.7.5 RECENT DEVELOPMENTS
16.8 BIOCEPT, INC.
16.8.1 COMPANY SNAPSHOT
16.8.2 REVENUE ANALYSIS
16.8.3 PRODUCT PORTFOLIO
16.8.4 RECENT DEVELOPMENTS
16.9 BIOMÉRIEUX
16.9.1 COMPANY SNAPSHOT
16.9.2 REVENUE ANALYSIS
16.9.3 PRODUCT PORTFOLIO
16.9.4 RECENT DEVELOPMENTS
16.1 BIO-RAD LABORATORIES, INC.
16.10.1 COMPANY SNAPSHOT
16.10.2 REVENUE ANALYSIS
16.10.3 PRODUCT PORTFOLIO
16.10.4 RECENT DEVELOPMENT
16.11 CEPHEID
16.11.1 COMPANY SNAPSHOT
16.11.2 REVENUE ANALYSIS
16.11.3 PRODUCT PORTFOLIO
16.11.4 RECENT DEVELOPMENT
16.12 EXACT SCIENCES CORPORATION
16.12.1 COMPANY SNAPSHOT
16.12.2 REVENUE ANALYSIS
16.12.3 COMPANY SHARE ANALYSIS
16.12.4 PRODUCT PORTFOLIO
16.12.5 RECENT DEVELOPMENTS
16.13 FUJIFILM CORPORATION
16.13.1 COMPANY SNAPSHOT
16.13.2 REVENUE ANALYSIS
16.13.3 PRODUCT PORTFOLIO
16.13.4 RECENT DEVELOPMENT
16.14 GENERAL ELECTRIC
16.14.1 COMPANY SNAPSHOT
16.14.2 REVENUE ANALYSIS
16.14.3 PRODUCT PORTFOLIO
16.14.4 RECENT DEVELOPMENTS
16.15 ILLUMINA, INC.
16.15.1 COMPANY SNAPSHOT
16.15.2 REVENUE ANALYSIS
16.15.3 PRODUCT PORTFOLIO
16.15.4 RECENT DEVELOPMENTS
16.16 MYRIAD GENETICS, INC.
16.16.1 COMPANY SNAPSHOT
16.16.2 REVENUE ANALYSIS
16.16.3 PRODUCT PORTFOLIO
16.16.4 RECENT DEVELOPMENT
16.17 NANOSTRING.
16.17.1 COMPANY SNAPSHOT
16.17.2 REVENUE ANALYSIS
16.17.3 PRODUCT PORTFOLIO
16.17.4 RECENT DEVELOPMENT
16.17.5 RECENT DEVELOPMENT
16.18 ONCOSTEM.
16.18.1 COMPANY SNAPSHOT
16.18.2 PRODUCT PORTFOLIO
16.18.3 RECENT DEVELOPMENT
16.19 PROVISTA DIAGNOSTICS.
16.19.1 COMPANY SNAPSHOT
16.19.2 PRODUCT PORTFOLIO
16.19.3 RECENT DEVELOPMENT
16.2 THERMO FISHER SCIENTIFIC INC.
16.20.1 COMPANY SNAPSHOT
16.20.2 REVENUE ANALYSIS
16.20.3 PRODUCT PORTFOLIO
16.20.4 RECENT DEVELOPMENT
17 QUESTIONNAIRE
18 RELATED REPORTS
表格列表
TABLE 1 INCIDENCE RATE OF BREAST CANCER (2020)
TABLE 2 MORTALITY RATE OF BREAST CANCER (2020)
TABLE 3 INCIDENCE OF DUCTAL CARCINOMA IN SITU (DCIS) BREAST CANCER
TABLE 4 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 5 MIDDLE EAST & AFRICA IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 6 MIDDLE EAST & AFRICA IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 7 MIDDLE EAST & AFRICA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 8 MIDDLE EAST & AFRICA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 9 MIDDLE EAST & AFRICA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 10 MIDDLE EAST & AFRICA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 11 MIDDLE EAST & AFRICA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 12 MIDDLE EAST & AFRICA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 13 MIDDLE EAST & AFRICA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 14 MIDDLE EAST & AFRICA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 15 MIDDLE EAST & AFRICA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 16 MIDDLE EAST & AFRICA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 17 MIDDLE EAST & AFRICA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 18 MIDDLE EAST & AFRICA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 19 MIDDLE EAST & AFRICA BLOOD TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 20 MIDDLE EAST & AFRICA OTHERS IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 21 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 22 MIDDLE EAST & AFRICA INVASIVE DUCTAL CARCINOMA IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 23 MIDDLE EAST & AFRICA DUCTAL CARCINOMA IN SITU IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 24 MIDDLE EAST & AFRICA INFLAMMATORY BREAST CANCER IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 25 MIDDLE EAST & AFRICA METASTATIC BREAST CANCER IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 26 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 27 MIDDLE EAST & AFRICA HOSPITALS IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 28 MIDDLE EAST & AFRICA DIAGNOSTIC CENTERS IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 29 MIDDLE EAST & AFRICA CLINICS IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 30 MIDDLE EAST & AFRICA RESEARCH AND ACADEMIC INSTITUTES IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 31 MIDDLE EAST & AFRICA OTHERS IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 32 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 33 MIDDLE EAST & AFRICA DIRECT TENDER IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 34 MIDDLE EAST & AFRICA RETAIL SALES IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 35 MIDDLE EAST & AFRICA OTHERS IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 36 MIDDLE EAST AND AFRICA BREAST CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 37 MIDDLE EAST AND AFRICA BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 38 MIDDLE EAST AND AFRICA IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 39 MIDDLE EAST AND AFRICA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 40 MIDDLE EAST AND AFRICA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 41 MIDDLE EAST AND AFRICA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 42 MIDDLE EAST AND AFRICA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 43 MIDDLE EAST AND AFRICA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 44 MIDDLE EAST AND AFRICA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 45 MIDDLE EAST AND AFRICA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 46 MIDDLE EAST AND AFRICA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 47 MIDDLE EAST AND AFRICA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 48 MIDDLE EAST AND AFRICA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 49 MIDDLE EAST AND AFRICA BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 50 MIDDLE EAST AND AFRICA BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 51 MIDDLE EAST AND AFRICA BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 52 EGYPT BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 53 EGYPT IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 54 EGYPT IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 55 EGYPT IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 56 EGYPT IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 57 EGYPT NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 58 EGYPT NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 59 EGYPT NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 60 EGYPT BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 61 EGYPT BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 62 EGYPT BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 63 EGYPT GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 64 EGYPT GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 65 EGYPT GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 66 EGYPT MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 67 EGYPT MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 68 EGYPT MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 69 EGYPT BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 70 EGYPT BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 71 EGYPT BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 72 SOUTH AFRICA BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 73 SOUTH AFRICA IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 74 SOUTH AFRICA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 75 SOUTH AFRICA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 76 SOUTH AFRICA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 77 SOUTH AFRICA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 78 SOUTH AFRICA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 79 SOUTH AFRICA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 80 SOUTH AFRICA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 81 SOUTH AFRICA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 82 SOUTH AFRICA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 83 SOUTH AFRICA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 84 SOUTH AFRICA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 85 SOUTH AFRICA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 86 SOUTH AFRICA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 87 SOUTH AFRICA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 88 SOUTH AFRICA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 89 SOUTH AFRICA BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 90 SOUTH AFRICA BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 91 SOUTH AFRICA BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 92 ISRAEL BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 93 ISRAEL IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 94 ISRAEL IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 95 ISRAEL IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 96 ISRAEL IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 97 ISRAEL NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 98 ISRAEL NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 99 ISRAEL NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 100 ISRAEL BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 101 ISRAEL BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 102 ISRAEL BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 103 ISRAEL GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 104 ISRAEL GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 105 ISRAEL GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 106 ISRAEL MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 107 ISRAEL MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 108 ISRAEL MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 109 ISRAEL BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 110 ISRAEL BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 111 ISRAEL BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 112 SAUDI ARABIA BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 113 SAUDI ARABIA IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 114 SAUDI ARABIA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 115 SAUDI ARABIA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 116 SAUDI ARABIA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 117 SAUDI ARABIA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 118 SAUDI ARABIA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 119 SAUDI ARABIA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 120 SAUDI ARABIA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 121 SAUDI ARABIA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 122 SAUDI ARABIA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 123 SAUDI ARABIA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 124 SAUDI ARABIA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 125 SAUDI ARABIA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 126 SAUDI ARABIA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 127 SAUDI ARABIA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 128 SAUDI ARABIA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 129 SAUDI ARABIA BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 130 SAUDI ARABIA BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 131 SAUDI ARABIA BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 132 UAE BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 133 UAE IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 134 UAE IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 135 UAE IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 136 UAE IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 137 UAE NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 138 UAE NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 139 UAE NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 140 UAE BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 141 UAE BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 142 UAE BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 143 UAE GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 144 UAE GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 145 UAE GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 146 UAE MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 147 UAE MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP
TABLE 148 UAE MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS)
TABLE 149 UAE BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 150 UAE BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 151 UAE BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 152 REST OF MIDDLE EAST AND AFRICA BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
图片列表
FIGURE 1 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTIC MARKET: SEGMENTATION
FIGURE 2 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTIC MARKET: DATA TRIANGULATION
FIGURE 3 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTIC MARKET: DROC ANALYSIS
FIGURE 4 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTIC MARKET: MIDDLE EAST & AFRICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTIC MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTIC MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTIC MARKET: MARKET END USER COVERAGE GRID
FIGURE 8 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTIC MARKET: DBMR MARKET POSITION GRID
FIGURE 9 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTIC MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTIC MARKET: SEGMENTATION
FIGURE 11 GROWING AWARENESS OF BREAST CANCER AND INCREASING HEALTHCARE EXPENDITURE IS EXPECTED TO DRIVE THE GROWTH OF THE MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTIC MARKET FROM 2023 TO 2030
FIGURE 12 THE IMAGING SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTIC MARKET IN 2023 & 2030
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET
FIGURE 14 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET : BY TEST TYPE, 2022
FIGURE 15 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET : BY TEST TYPE, 2023-2030 (USD MILLION)
FIGURE 16 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET : BY TEST TYPE, CAGR (2023-2030)
FIGURE 17 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET : BY TEST TYPE, LIFELINE CURVE
FIGURE 18 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET : BY TYPE, 2022
FIGURE 19 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET : BY TYPE, 2023-2030 (USD MILLION)
FIGURE 20 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET : BY TYPE, CAGR (2023-2030)
FIGURE 21 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET : BY TYPE, LIFELINE CURVE
FIGURE 22 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET : BY END USER, 2022
FIGURE 23 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET : BY END USER, 2023-2030 (USD MILLION)
FIGURE 24 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET : BY END USER, CAGR (2023-2030)
FIGURE 25 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET : BY END USER, LIFELINE CURVE
FIGURE 26 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET : BY DISTRIBUTION CHANNEL, 2022
FIGURE 27 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET : BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)
FIGURE 28 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET : BY DISTRIBUTION CHANNEL, CAGR (2023-2030)
FIGURE 29 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET : BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 30 MIDDLE EAST AND AFRICA BREAST CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022)
FIGURE 31 MIDDLE EAST AND AFRICA BREAST CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022)
FIGURE 32 MIDDLE EAST AND AFRICA BREAST CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030)
FIGURE 33 MIDDLE EAST AND AFRICA BREAST CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030)
FIGURE 34 MIDDLE EAST AND AFRICA BREAST CANCER DIAGNOSTICS MARKET: TEST TYPE (2023-2030)
FIGURE 35 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%)
研究方法
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
可定制
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.